Tentando aprender a traduzir a partir dos exemplos de tradução humana.
De: Tradução automática
Sugerir uma tradução melhor
Qualidade:
A partir de tradutores profissionais, empresas, páginas da web e repositórios de traduções disponíveis gratuitamente
moderately to severely active ulcerative colitis moderately to severely active crohn’s disease.
μέτρια έως σοβαρή ενεργό ελκώδη κολίτιδα μέτρια έως σοβαρή ενεργό νόσο του crohn.
Última atualização: 2017-04-26
Frequência de uso: 1
Qualidade:
treatment of active ulcerative colitis
treatment of active ulcerative colitis
Última atualização: 2011-10-23
Frequência de uso: 2
Qualidade:
Aviso: esta concordância pode estar incorreta.
Exclua-a, se este for o caso.
moderately to severely active crohn’s disease
Μέτρια έως σοβαρή, ενεργή νόσος του crohn
Última atualização: 2017-04-26
Frequência de uso: 1
Qualidade:
ulcerative colitis
Ελκώδης κολίτιδα
Última atualização: 2017-04-26
Frequência de uso: 9
Qualidade:
ulcerative colitis.
Ελκώδη κολίτιδα.
Última atualização: 2017-04-26
Frequência de uso: 1
Qualidade:
adults with moderately to severely active ulcerative colitis (a disease causing inflammation and ulcers in the lining of the gut);
ενήλικες με μέτριας έως σοβαρής μορφής ενεργή ελκώδη κολίτιδα (νόσος που προκαλεί φλεγμονή και έλκη στα εσωτερικά τοιχώματα του εντέρου)
Última atualização: 2017-04-26
Frequência de uso: 1
Qualidade:
severe ulcerative colitis
Σοβαρή ελκώδης κολίτιδα
Última atualização: 2017-04-26
Frequência de uso: 4
Qualidade:
severe ulcerative colitis.
Σοβαρή ελκώδη κολίτιδα
Última atualização: 2017-04-26
Frequência de uso: 5
Qualidade:
maintenance treatment in moderately to severely active crohn’s disease in adults
Θεραπεία συντήρησης στη μέτρια έως σοβαρή, ενεργή νόσο crohn σε ενήλικες
Última atualização: 2017-04-26
Frequência de uso: 1
Qualidade:
study iii evaluated 619 patients with moderately to severely active rheumatoid arthritis who were 18 t uc
λέ Η Μελέτη ΙΙΙ αξιολόγησε 619 ασθενείς με μέτρια έως σοβαρή ενεργό ρευματοειδή αρθρίτιδα, οι
Última atualização: 2008-03-04
Frequência de uso: 2
Qualidade:
Aviso: esta concordância pode estar incorreta.
Exclua-a, se este for o caso.
study iii evaluated 619 patients with moderately to severely active rheumatoid arthritis who were ≥ 18 lp
ί ας χορηγήθηκε κανένα άλλο τροποποιητικό της νόσου αντιρευµατικό φάρµακο.
Última atualização: 2011-10-23
Frequência de uso: 1
Qualidade:
Aviso: esta concordância pode estar incorreta.
Exclua-a, se este for o caso.
study iii evaluated 619 patients with moderately to severely active rheumatoid arthritis who were ≥ 18 t uc
λέ Η Μελέτη ΙΙΙ αξιολόγησε 619 ασθενείς µε µέτρια έως σοβαρή ενεργό ρευµατοειδή αρθρίτιδα, οι
Última atualização: 2012-04-11
Frequência de uso: 2
Qualidade:
patients aged 4 to 17 years with moderately to severely active polyarticular juvenile idiopathic arthritis refractory to or
Περιλήφθηκαν ασθενείς ηλικίας 4 έως 17 ετών με μέτρια έως σοβαρή ενεργή νεανική ιδιοπαθή πολυαρθρίτιδα που παρουσιάζουν αντοχή ή δυσανεξία στη θεραπεία με μεθοτρεξάτη.
Última atualização: 2008-03-04
Frequência de uso: 2
Qualidade:
Aviso: esta concordância pode estar incorreta.
Exclua-a, se este for o caso.
study iv primarily assessed safety in 636 patients with moderately to severely active rheumatoid arthritis who were 18 years old.
Η Μελέτη Ιv αξιολόγησε κυρίως την ασφάλεια σε 636 ασθενείς με μέτρια έως σοβαρή ενεργό ρευματοειδή αρθρίτιδα, οι οποίοι ήταν 18 ετών.
Última atualização: 2008-03-04
Frequência de uso: 4
Qualidade:
Aviso: esta concordância pode estar incorreta.
Exclua-a, se este for o caso.
ra studies vi and vii each evaluated 60 patients with moderately to severely active rheumatoid arthritis who were ≥ 18 years old.
Οι μελέτες ra vi και vii αξιολόγησαν 60 ασθενείς η κάθε μια, με μέτρια έως σοβαρή ενεργό ρευματοειδή αρθρίτιδα, οι οποίοι ήταν ≥ 18 ετών.
Última atualização: 2017-04-26
Frequência de uso: 1
Qualidade:
the single and multiple dose pharmacokinetics of vedolizumab have been studied in healthy subjects and in patients with moderate to severely active ulcerative colitis or crohn’s disease.
Η φαρμακοκινητική του vedolizumab για μία και για πολλαπλές δόσεις έχει μελετηθεί σε υγιή υποκείμενα και σε ασθενείς με μέτρια έως σοβαρή ενεργό ελκώδη κολίτιδα ή νόσο του crohn.
Última atualização: 2017-04-26
Frequência de uso: 1
Qualidade:
treatment of moderately to severely active ulcerative colitis in patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mp or aza, or who are intolerant to or have medical contraindications for such therapies.
2 Τη θεραπευτική αντιμετώπιση της μετρίως έως σοβαρώς ενεργούς ελκώδους κολίτιδας σε ασθενείς οι οποίοι είχαν ανεπαρκή ανταπόκριση στη συμβατική θεραπεία συμπεριλαμβανομένων των κορτικοστεροειδών και των 6- mp ή aza, ή οι οποίοι είναι δυσανεκτικοί σε ή έχουν ιατρικές αντενδείξεις για τέτοιες θεραπείες.
Última atualização: 2012-04-11
Frequência de uso: 3
Qualidade:
the reduction in incidence of colectomy was also examined in another randomised, double-blind study (c0168y06) in hospitalised patients (n= 45) with moderately to severely active ulcerative colitis who
Η μείωση στη συχνότητα εμφάνισης της κολεκτομής εξετάσθηκε επίσης σε μία άλλη τυχαιοποιημένη, διπλά τυφλή μελέτη (c0168y06) σε ασθενείς εισηγμένους σε νοσοκομείο (n= 45) με μετρίως έως σοβαρώς ενεργή ελκώδη κολίτιδα που απέτυχαν να ανταποκριθούν σε iv κορτικοστεροειδή και οι οποίοι ήταν συνεπώς σε υψηλότερο κίνδυνο για κολεκτομή.
Última atualização: 2012-04-11
Frequência de uso: 2
Qualidade:
entyvio is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (tnfα) antagonist.
Το entyvio ενδείκνυται για τη θεραπεία ενήλικων ασθενών με μέτρια έως σοβαρή, ενεργό ελκώδη κολίτιδα, οι οποίοι είχαν ανεπαρκή ανταπόκριση, έχασαν την ανταπόκριση ή παρουσίασαν δυσανεξία είτε στη συμβατική θεραπεία είτε σε ανταγωνιστή του παράγοντα νέκρωσης όγκων άλφα (tnfα).
Última atualização: 2017-04-26
Frequência de uso: 1
Qualidade:
in patients with moderately to severely active paediatric crohn’s disease, the rate of anti-adalimumab antibody development in patients receiving adalimumab was 3.3%.
Σε ασθενείς με μέτρια έως σοβαρή ενεργό παιδιατρική νόσο του crohn, ο ρυθμός ανάπτυξης anti- adalimumab αντισωμάτων σε ασθενείς που έλαβαν adalimumab ήταν 3,3%.
Última atualização: 2017-04-26
Frequência de uso: 1
Qualidade: